Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Alix Ventures is a venture capital firm established to invest in early-stage life science startups that engineer biology for advancements in human health. Founded by a team of experienced life science entrepreneurs, the firm leverages their backgrounds in raising capital, scaling teams, and operating startups to support innovative companies. Alix Ventures is headquartered in the United States and is dedicated to partnering with accomplished founders to address critical challenges in the life sciences sector.
Currently, Alix Ventures manages a portfolio of 14 companies, focusing exclusively on the U.S. market. The firm emphasizes investments in the emerging 'TechBio' landscape, which merges technology with biology to create impactful solutions. Notable milestones include the acquisition of Circularis by Ginkgo Bioworks, showcasing the firm's ability to identify and support high-potential startups.
Alix Ventures concentrates its investments in the life sciences sector, particularly in companies that are part of the TechBio landscape. This includes startups developing innovative solutions in drug development, tech-enabled diagnostics, genomic data platforms, and clinical trial platforms. The firm seeks to invest in companies that demonstrate a clear potential for patient impact, aligning with its mission to drive advancements in human health.
Investment stages include pre-seed, seed, and seed-plus, allowing Alix Ventures to engage with startups at various points in their development. The firm does not invest in international companies, single indication diagnostics, medical devices, or wellness-related applications, ensuring a focused approach to its investment strategy.
Alix Ventures has built a diverse portfolio of 14 companies, each contributing to advancements in the life sciences sector. Notable portfolio companies include:
This portfolio reflects Alix Ventures' commitment to supporting innovative companies that integrate technology and biology to improve human health outcomes.
Chas Pulido: Founder & General Partner. Chas has extensive experience in the life sciences sector, having previously founded and scaled multiple startups. His expertise lies in capital raising and operational management.
Nick Goldner: Venture Partner. Nick brings a wealth of knowledge in venture capital and startup operations, having worked with various life science companies throughout his career.
Mark Pulido: Operating Partner. Mark has a strong background in managing early-stage companies and provides operational support to portfolio firms.
Brian Fiske: SAB Member - Drug Development. Brian is an expert in drug development, contributing valuable insights to the firm's investment decisions.
Daniel Delubac: SAB Member - Diagnostics/Lab Services. Daniel specializes in diagnostics and lab services, enhancing the firm's understanding of this critical area.
Jake Becraft: SAB Member - Syn Bio / CGT. Jake focuses on synthetic biology and cell and gene therapy, providing expertise that aligns with Alix Ventures' investment focus.
To pitch Alix Ventures, founders should visit their website at alix.vc. The firm prefers pitches that clearly outline the startup's mission, the problem it addresses, and the innovative solutions it offers. A well-structured deck that includes market analysis, competitive landscape, and team backgrounds is essential. Response times may vary, so founders should be prepared for a thorough review process.
In recent months, Alix Ventures has continued to expand its portfolio, focusing on early-stage life science startups. Notable activity includes the acquisition of Circularis by Ginkgo Bioworks, which highlights the firm's ability to identify high-potential companies. The firm remains committed to supporting innovative solutions in the TechBio landscape, with ongoing investments in companies that drive patient impact.
As of October 2023, Alix Ventures has maintained its focus on the U.S. market, ensuring that its investments align with its strategic goals in the life sciences sector.
What are Alix Ventures' investment criteria?
Alix Ventures invests in early-stage life science companies, particularly those in the TechBio sector. They focus on startups developing solutions in drug development, tech-enabled diagnostics, genomic data platforms, and clinical trial platforms.
How can I pitch to Alix Ventures?
Founders can submit their pitches through the Alix Ventures website at alix.vc. The firm does not provide specific email addresses for pitches.
What makes Alix Ventures different from other investors?
Alix Ventures is distinct in its exclusive focus on the U.S. life sciences market and its commitment to partnering with accomplished founders who are addressing significant challenges in the sector.
What is the typical check size for investments?
While specific check sizes are not disclosed, Alix Ventures invests at the pre-seed, seed, and seed-plus stages, indicating a range that typically aligns with early-stage funding.
What is the firm's post-investment involvement like?
Alix Ventures actively supports its portfolio companies through mentorship and operational guidance, leveraging the team's extensive experience in the life sciences sector.
What types of companies does Alix Ventures avoid?
The firm does not invest in international companies, single indication diagnostics, medical devices, or wellness-related applications, maintaining a focused investment strategy.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.